Cowen Raises Price Target on Aquinox Pharma (AQXP) Following R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Leerink Partners Remains Bullish on Aquinox Pharma (AQXP) Following Investor Day
October 8, 2015 8:32 AM EDTLeerink Partners reiterated an Outperform rating and $26.00 price target on Aquinox Pharmaceutical (NASDAQ: AQXP) after attending an investor day. At the event, the company unveiled the AQX-1125 Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) Phase III design it plans propose to FDA at its endof-Phase II meeting in 4Q15.
Analyst Paul Matteis commented,... More
